SARS-CoV-2 lung disease in a patient with pulmonary sarcoidosis - case report

Adv Respir Med. 2020;88(6):620-625. doi: 10.5603/ARM.a2020.0199.

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the recently identified cause of the current pandemic. In patients with chronic respiratory lung diseases, SARS-CoV-2 may result in significant morbidity and increased mortality. We present a case of a 69-year-old male with stage II pulmonary sarcoidosis who had been under observation for 30 months without immunosuppressive treatment. He then developed severe SARS-CoV-2 disease with typical radiological and laboratory findings. Therapy with oxygen, antibiotics, low-molecular-weight heparin in a prophylactic dose, and dexamethasone resulted in marked clinical improvement. We will discuss the rationale for corticosteroid use in both SARS-CoV-2 disease and in SARS-CoV-2 disease that is complicating comorbid sarcoidosis.

Keywords: SARS-CoV-2; anticoagulation; computed tomography; corticosteroids; sarcoidosis.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Anti-Bacterial Agents / therapeutic use
  • COVID-19 / complications*
  • COVID-19 / therapy*
  • COVID-19 Drug Treatment
  • Critical Care / methods
  • Heparin, Low-Molecular-Weight / therapeutic use
  • Humans
  • Hyperbaric Oxygenation / methods
  • Male
  • Sarcoidosis, Pulmonary / complications*
  • Sarcoidosis, Pulmonary / drug therapy
  • Sarcoidosis, Pulmonary / therapy*

Substances

  • Anti-Bacterial Agents
  • Heparin, Low-Molecular-Weight